Cite
Zhang D, Shah NJ, Cook M, et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13236109.
Zhang, D., Shah, N. J., Cook, M., Blackburn, M., Serzan, M. T., Advani, S., Potosky, A. L., Atkins, M. B., & Braithwaite, D. (2021). Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers, 13(23), . https://doi.org/10.3390/cancers13236109
Zhang, Dongyu, et al. "Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13236109
Zhang D, Shah NJ, Cook M, Blackburn M, Serzan MT, Advani S, Potosky AL, Atkins MB, Braithwaite D. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers (Basel). 2021 Dec 03;13(23). doi: 10.3390/cancers13236109. PMID: 34885219; PMCID: PMC8657283.
Copy
Download .nbib
